REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Strategic Platform License with TG Therapeutics

MaxCyteAnnouncement

12/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250212:nRSL7610Wa&default-theme=true

RNS Number : 7610W  MaxCyte, Inc.  12 February 2025

 

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its
Autoimmune Cell Therapeutics Programs

 

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and
ExPERT™ platform to support the development and commercialization of
azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of
autoimmune diseases

 

ROCKVILLE, MD, February 12, 2024 - MaxCyte, Inc.
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzoyNjMzMDI1YWJiNjI2ODFhMjIxMTg4ZDhiYWUxMTY4MTo2OmRiMmE6ZTJiYzkzOGJmMTdjOTU5NDBmMzRiMmI2Yjg1YzFkZTU1YTMzZmIwOGY5NTFmNzQ2ZDZlZjFjNTU1MTZjZjIyYjpwOlQ6Rg)
, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell-based therapeutics, today
announced they are entering into a strategic platform license (SPL) with TG
Therapeutics
(https://protect.checkpoint.com/v2/___https:/www.tgtherapeutics.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzoyNjMzMDI1YWJiNjI2ODFhMjIxMTg4ZDhiYWUxMTY4MTo2OjhhNTM6NjExZDkwMDk0M2IxZDZhNzBiZGFkNDQ0NzZiMDRjYjMwMDllNWE3Y2FiNzM0MzRlZDQ1MDYzYTU5NzY4MDRjNDpwOlQ6Rg)
, a fully integrated, commercial stage, biopharmaceutical company focused on
the acquisition, development and commercialization of novel treatments for
B-cell diseases.

 

Under the terms of the agreement, TG Therapeutics obtains non-exclusive
research, clinical and commercial rights to use MaxCyte's Flow
Electroporation® technology and ExPERT™ platform. In return, MaxCyte is
entitled to receive annual licensing fees and program-related revenue.

 

TG Therapeutics entered into an agreement with Precision BioSciences, Inc. and
acquired a worldwide license to Precision's Azercabtagene Zapreleucel
(azer-cel), an investigational allogeneic or "off the shelf" CD19 CAR T cell
therapy program for autoimmune diseases and all other non-oncology
indications. TG received clearance by the U.S. Food and Drug Administration
(FDA) of an Investigational New Drug (IND) application for azer-cel in
progressive forms of multiple sclerosis (MS) and is targeting commencement of
a Phase 1 trial in 2025.

 

"By leveraging our commercially validated cell-engineering platform and
optimized T cell manufacturing workflow, TG Therapeutics is advancing toward
their Phase 1 clinical trial for the application of azer-cel in progressive
forms of MS," said Maher Masoud, President and CEO of MaxCyte. "Our
technology has been integral to the manufacturing of allogeneic T cell
immunotherapies and was efficiently transferred from Precision BioSciences
when TG Therapeutics obtained global rights for azer-cel
(https://protect.checkpoint.com/v2/___https:/ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-global-license-agreement-precision___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzoyNjMzMDI1YWJiNjI2ODFhMjIxMTg4ZDhiYWUxMTY4MTo2OmQxZmY6MGRkYzc0ZWU0YTZlN2ZhYTcyMWE3MzRmYjcxYjFjMTM4MDMyYmNhMmFiYWZhYjliMWE4NzIwOGZmNzM0MTVlNTpwOlQ6Rg)
for autoimmune diseases in January 2024. With our new partnership, we will
continue to support the development of azer-cel to expand the application to
autoimmune diseases."

 

MaxCyte's ExPERT™ instrument portfolio is the next generation of leading,
clinically and commercially validated electroporation technology for complex
and scalable cell engineering. By delivering high transfection efficiency and
cell viability, seamless scalability and enhanced functionality, the ExPERT™
platform delivers the high-end performance essential to enabling the next wave
of biological and cellular therapeutics.

 

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 25 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more
at maxcyte.com
(https://www.globenewswire.com/Tracker?data=VYz5wLS7zaAAoN9LcLPBR4K2MnQZ7IsnPHU-Z7siYzZvtH_081o4EbGn3c1jQFc0JVUZlfM5I10g6XpeYFABe57YicaMkwUAVkNifWQuvsYUB7YHJmaI8gpitgEIayD7BcXPat283B53SQ2dZCy0QuYBo9BNxBlrUuD4tfgCuL1nWW3-_mGuvDnufc5FbnusLXrOxvAYXInVbl5WylYNwz1CJ3dNpy8g8IKg3sizT6LyUM1jczb-H2K4bMtFuwTDczuPL84V5nE1ZEJMQjllUClDOoHO1Vg9BapCdoj06aBZ-_0drNUy9pPrGgiYLWTNBrN6IqqKQNHBTuSYA0wOlDaAjtPRlbou81yPGCxdzYdcdAaydDjiEs4a89ghd749)
 and follow us on X
(https://www.globenewswire.com/Tracker?data=IbRJmFs-y6pmwrAyLFg0mBnvpwSn8mJ8PicnKQyM5DTUN2UqSB2u2I6lhcod3y91qEb9XeJ-LH6zEKvBufEzIhVe5vzIj9qvJ9d2Z362sJW4Z3hBoQikJwHZm-2BArfT4O4JYOb2ptDQ4AYJjIllHJbcsajTS4uqIBOibIoxLnF3_Ab01p2mDmpFkutg4yxfDRVyc2hfslMZEtnZ0tGgG4fq4xi0msknRTxNNy6Qd5ZMA7TW97ToXvKHqpk3Wwtz8Zkq1UEbrpLE3JvclNckuunrZLIhLhznZu5Wzl6nrOu8nn0OqImPz_nUmXosXzxt91UValO4GN447t6C3p3_JwWcyZHLK_mJ443JQwWL_bAyXs7yi6Zoic9bUMHS9yQf)
 and LinkedIn
(https://www.globenewswire.com/Tracker?data=x6qH8WZauZRry1BDg_FTfWfdxBynO-n3z9TGSjgV1E3rFwfdpbA5EYfK1AACMZURFIjjj7ifHiSmZj6ojTv_ff6ZqAnV3-buNxCZ-IfST5BpHAW44yrh7Dw9iK0AcjERb05mN-dFQIqirR-fhsubtwgVeArvfNldbRbsxQ6Yk2sS18qH4KJZGow01s6NAz_ua9JDOurVdG9ScE6J8nUf-c7jk2wwdCwLBdeAS_WXKE0Qpgvg_KLzKtse0Flc7uPZhrqSI8IRD96w12x-VXP4HapTfm6MmgrzkkZbyfHo7YS3dLB7lg2hOrvOJ8ojsxyMqQUujJHacfK0i7PtV-nOD6hYY6rjxVVRh89BDxi8kmU9viJiNTZAFB7fGFaL0y_NkXLCp1tvNdIaOnGVl_MfCw==)
.

 

About TG Therapeutics

TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical
company focused on the acquisition, development, and commercialization of
novel treatments for B-cell diseases. In addition to a research pipeline
including several investigational medicines, TG Therapeutics has received
approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI®
(ublituximab-xiiy) for the treatment of adult patients with relapsing forms of
multiple sclerosis, including clinically isolated syndrome,
relapsing-remitting disease, and active secondary progressive disease, as well
as approval by the European Commission (EC) and the Medicines and Healthcare
Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS
who have active disease defined by clinical or imaging features in Europe and
the United Kingdom, respectively. For more information,
visit tgtherapeutics.com
(https://protect.checkpoint.com/v2/___https:/www.tgtherapeutics.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzoyNjMzMDI1YWJiNjI2ODFhMjIxMTg4ZDhiYWUxMTY4MTo2OjhhNTM6NjExZDkwMDk0M2IxZDZhNzBiZGFkNDQ0NzZiMDRjYjMwMDllNWE3Y2FiNzM0MzRlZDQ1MDYzYTU5NzY4MDRjNDpwOlQ6Rg)
, and follow us on X
(https://protect.checkpoint.com/v2/___https:/x.com/TGTherapeutics___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzoyNjMzMDI1YWJiNjI2ODFhMjIxMTg4ZDhiYWUxMTY4MTo2OjM0NjA6ODJkMzA4NWU2MzhiNTQ4YTBlMTEyY2FmNDU1OWQ1ZGUwNTk0NmZjYmJhODMyZGY2MGNjYjE1ZmRhZjRhYTY2MzpwOlQ6Rg)
(formerly Twitter) and on LinkedIn
(https://protect.checkpoint.com/v2/___https:/www.linkedin.com/company/tg-therapeutics/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzoyNjMzMDI1YWJiNjI2ODFhMjIxMTg4ZDhiYWUxMTY4MTo2OjdmYmQ6NjBjMTBkMGQxMDRkMTRhYTVlMzhkYjBkZWM5OWQ4MWNhOTFmYTkwZDhhMGUyOTU3MmVmZGJjNWU5MzYxMDAyNTpwOlQ6Rg)
.

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Science

Jordan Vines

jvines@spectrumscience.com (mailto:jvines@spectrumscience.com)

+1 540-629-3137

 

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@icrhealthcare.com (mailto:maxcyte@icrhealthcare.com)

 

TG Therapeutics Contact:

 

Investor Relations

Email: ir@tgtxinc.com
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=ri10HujD25rQ-Sg7_efMpNVmQ3lESJBd5z2Jr-uWn-uMPEImW_kl_COvtQtj2lTDM0ufiYjGxg2K84Z4Fi0gTg==___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzoyNjMzMDI1YWJiNjI2ODFhMjIxMTg4ZDhiYWUxMTY4MTo2OmRkMDA6NDM4MTc2NTIwYWQxZjhmMmM4NzEwYWQ0MWRkMTEyNjhhNmExOTQ2M2ZmMTE4ZGFjZDY2Mzg0YTBmYjY3ZTkwZDpwOlQ6Rg)

Telephone: 1.877.575.TGTX (8489), Option 4

 

Media Relations

Email: media@tgtxinc.com
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=XxlRfgxtizHuyMxSEFPBGF7BSK93SOUsKOyMU7eIHEKQr9wfQCv-m1lhrYpMmKOg0v8BqgcMMrsp8DpZzxRHYTN6t-EdpMtSnoMKPiWveoI=___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzoyNjMzMDI1YWJiNjI2ODFhMjIxMTg4ZDhiYWUxMTY4MTo2OmY1M2M6OWFkNDM2NDAxMWE3Yzc5NmM3NWFiNjk2MDg0OTViNDhjNjc4Y2M0YTk0NWQ5ZTNlYzhmZjRmMTNlMjg2Nzk2MzpwOlQ6Rg)

Telephone: +1 877-575-TGTX (8489), Option 6

 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. All statements other than statements of historical facts contained in
this press release, including statements regarding our future results of
operations or financial condition, business strategy and plans and objectives
of management for future operations, are forward-looking statements. These
statements are inherently uncertain, and investors are cautioned not to unduly
rely on these statements.

 

Risks and uncertainties related to our business are described in greater
detail in Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the Securities and Exchange Commission ("SEC")
on March 12, 2024, as well as in discussions of potential risks,
uncertainties, and other important factors in the other filings that we make
with the Securities and Exchange Commission from time to time, including in
our Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on
November 6, 2024. These documents are available through the Investor Menu,
Financials section, under "SEC Filings" on the Investors page of our website
at http://investors.maxcyte.com
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=q2oLhyU6o2omjw3BHBtsmVGfHAufRRlBD-KtE7SzBKO1rmm7SNgKaW_zqkwmnGlLUojrkS6R1wa3gVTYck893OkTPFR2kuVVDfS6EAlVHu5FhL8zM4aXU72klSuqgBbMXfpuDFdNgioTUsyqM9kzl2D3iu9_ASFbXMHPWgecOTP4oBwyF_c-jy2JAi-i1LjGCSCCqM-9yraRBEChnovh0k9p0GYslj9F47PUjEe2Q8CQwiNljHI3Kpokz9V6CB4zQrDcbe7A9XMsbV7ryQVWooEMBEHTDAAHj48bsPofTUVvUUhi7PTeNCw3yquBicqfNPzmTzlqAuECsXl3ECe1cNAsqpJXTpnZmOdiajlkajYawyC2N115CL2Nyj8ZlC5Fdr78Q118owDqHJ8qMhH3bg==___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzoyNjMzMDI1YWJiNjI2ODFhMjIxMTg4ZDhiYWUxMTY4MTo2OmY2OTM6ODc5YWM3ZTIyZTZhZDdhNzcwNzhiYzY3ZTRiYzNlNTI1NGQ5OWU5YWFmOTVlYjdjZjkzMjA4ZWQ3ZDc3MGNlODpwOlQ6Rg)
. Any forward-looking statements in this press release are based on our
current beliefs and opinions on the relevant subject based on information
available to us as of the date of such press release, and you should not rely
on forward-looking statements as predictions of future events. We undertake no
obligation to update any forward-looking statements made in this press release
to reflect events or circumstances after the date of this press release or to
reflect new information or the occurrence of unanticipated events, except as
required by law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUARURVAUUAUR